The Adis Journals team is celebrating the recent publication of the 2014 Journal Citation Reports® which revealed double-digit growth in the Impact Factor for seven of its titles over the previous year.
Of the sixteen Adis Journals currently listed in the reports, eleven saw an increase in this latest announcement. Six journals have Impact Factors that rank in the top quartile of their subject category including Clinical Pharmacokinetics, CNS Drugs, Drug Safety, Drugs, PharmacoEconomics and American Journal of Clinical Dermatology. Two Adis journals now have an Impact Factor above 5; CNS Drugs with an Impact Factor of 5.113, and Clinical Pharmacokinetics with an Impact Factor of 5.053.
The most significant growth was for BioDrugs, a journal that covers the development and use of biotechnology-based pharmaceuticals and innovative technologies for the treatment of human disease. The journal has a new Impact Factor of 2.989 as a result of an astonishing 41% increase.Other titles achieving substantial improvements include the European Journal of Drug Metabolism and Pharmacokinetics and Targeted Oncology with impressive gains of 19.1% and 15.7% respectively.
The Journal Citation Reports® from Thomson Reuters provide a measure of a journal’s impact, with the Impact Factor representing the number of times an article from each title is cited on average.
Adis is a leading publishing of drug therapy-focused medical journals with a portfolio of over 30 titles. Their journals offer reputable and independent content of interest to anyone involved in medical research, practice or teaching; drug regulation or reimbursement; or those in the pharmaceutical industry.